

**GEOVAX LABS, INC.**  
**Condensed Consolidated Statements of Operations Information**  
(amounts in thousands, except per share data)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2018	2017	2018	2017
Grant and collaboration revenue	\$ 93	\$ 352	\$ 315	\$ 648
Operating expenses:				
Research and development	372	518	859	1,070
General and administrative	359	352	717	645
	<u>731</u>	<u>870</u>	<u>1,576</u>	<u>1,715</u>
Loss from operations	(638)	(518)	(1,261)	(1,067)
Other income (expense), net	1	1	2	2
Net loss	<u>\$ (637)</u>	<u>\$ (517)</u>	<u>\$ (1,259)</u>	<u>\$ (1,065)</u>
Loss per common share	<u>\$ (0.00)</u>	<u>\$ (0.01)</u>	<u>\$ (0.01)</u>	<u>\$ (0.02)</u>

**GEOVAX LABS, INC.**  
**Condensed Consolidated Balance Sheet Information**  
(amounts in thousands)

	June 30, 2018	Dec. 31, 2017
Assets:		
Cash and cash equivalents	\$ 191	\$ 313
Other current assets	148	135
Total current assets	<u>339</u>	<u>448</u>
Property, net	21	31
Other assets	11	11
Total assets	<u>\$ 371</u>	<u>\$ 490</u>
Liabilities and stockholders' equity (deficiency)		
Current liabilities	\$ 1,068	\$ 811
Note payable, net of current portion	46	-
Stockholders' equity (deficiency)	(743)	(321)
Total liabilities and stockholders' equity (deficiency)	<u>\$ 371</u>	<u>\$ 490</u>
Common shares outstanding	164,737	106,737